| same as their interim results 89 | 4.879 | Jump to 5.68 |  |  | 
              
                
                  | or death when given within three days of | 5.2 | Jump to 10.559 |  |  | 
              
                
                  | symptoms to high-risk patients it was 88 | 4.48 | Jump to 12.639 |  |  | 
              
                
                  | when given within five days which | 3.121 | Jump to 15.759 |  |  | 
              
                
                  | versus 12 on placebo and these data are | 5.04 | Jump to 22.96 |  |  | 
              
                
                  | the company also for the first time | 4.24 | Jump to 37.36 |  |  | 
              
                
                  | alleviation of four straight days of | 4.48 | Jump to 56.48 |  |  | 
              
                
                  | seventy percent also both studies showed | 5.92 | Jump to 62.879 |  |  | 
              
                
                  | a tenfold decrease in viral load at five | 5.2 | Jump to 65.68 |  |  | 
              
                
                  | merck's results go from about a 50 | 4.081 | Jump to 87.119 |  |  | 
              
                
                  | death risk down to 30 percent in the | 3.919 | Jump to 91.2 |  |  | 
              
                
                  | meeting was november 30th it was two | 3.44 | Jump to 139.68 |  |  | 
              
                
                  | between the 89 number and the 70 number | 5.519 | Jump to 163.44 |  |  | 
              
                
                  | yeah so there were two separate trials | 5.04 | Jump to 169.04 |  |  | 
              
                
                  | the 89 number was in folks who have risk | 5.6 | Jump to 171.12 |  |  | 
              
                
                  | trial the 70 that was folks who are | 4.881 | Jump to 184.159 |  |  | 
              
                
                  | significant at 70 percent | 3.92 | Jump to 199.2 |  |  |